Resultados de procura - Bangxian Tan

  • Mostrando 1 - 4 Resultados de 4
Limitar resultados
  1. 1
    Current clinical application of lutetium‑177 in solid tumors (Review)

    Current clinical application of lutetium‑177 in solid tumors (Review) por Tingting Niu, Fan Mi, Binwei Lin, Feng Gao, Bangxian Tan, Xiaobo Du

    Publicado 2024
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  2. 2
    Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE)

    Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE) por Yuankai Shi, Jianhua Chen, Runxiang Yang, Hongbo Wu, Zhehai Wang, Weihua Yang, Jiuwei Cui, Yiping Zhang, Chunling Liu, Ying Cheng, Yunpeng Liu, Jinlu Shan, Donglin Wang, Lei Yang, Chang-Lu Hu, Jian Zhao, Ranhua Cao, Bangxian Tan, Ke Xu, Meimei Si, Hui Li, Ruifeng Mao, Lingyan Li, Xiaoyan Kang, Lin Wang

    Publicado 2024
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer

    Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer por Xiaoshan Wang, Yifeng Bai, Vivek Verma, Ruilian Yu, Wei Tian, Rui Ao, Ying Deng, Zhu Xueqiang, Hao Liu, Haixia Pan, Lan Yang, Hansong Bai, Xing Luo, Yan Guo, Mingxiu Zhou, Yuemei Sun, Zi-Can Zhang, Simin Li, Xue Cheng, Bangxian Tan, Liang-Fu Han, Yingyi Liu, Kai Zhang, Fanxin Zeng, Lin Jia, Xinbao Hao, You‐Yu Wang, Gang Feng, Ke Xie, You Lü, Ming Zeng

    Publicado 2022
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)

    Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT... por Yuankai Shi, Jianhua Chen, Helong Zhang, Zhihong Zhang, Yiping Zhang, Zhehai Wang, Shucai Zhang, Jian Zhao, Chunling Liu, Xiuwen Wang, Yanqiu Zhao, Chang-Lu Hu, Lei Yang, Xuezhi Hao, Lin Wang, Yunpeng Liu, Yan Yu, Jun Zhao, Mengzhao Wang, Liangming Zhang, Sanyuan Sun, Yanping Hu, Kangsheng Gu, Xiaosheng Hang, Jinlu Shan, Yu Zhang, Bangxian Tan, Weihua Yang, Runxiang Yang, Meimei Si, Huaize Geng, Hui Li, Xiaoyan Kang

    Publicado 2023
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: